Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
This investigator-initiated, double-blind, placebo-controlled study evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with.